Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8534565 | 0.84 | KMT2A (0.45) | MEN1KMT2AELANEALDH1A1HCRTR1 | |
| SCHEMBL23396000 | 0.79 | CYP2D6 (0.41) | VDRALDH1A1 | |
| SCHEMBL17824258 | 0.79 | CYP2D6 (0.41) | VDRALDH1A1 | |
| SCHEMBL17824085 | 0.79 | CYP2D6 (0.41) | VDRALDH1A1 | |
| SCHEMBL12018716 | 0.78 | P2RX7 (0.44) | MEN1KMT2AP2RX7HCRTR1HCRTR2 | |
| SCHEMBL20637914 | 0.78 | P2RX7 (0.44) | MEN1KMT2AP2RX7HCRTR1HCRTR2 | |
| SCHEMBL6133023 | 0.78 | P2RX7 (0.45) | MEN1KMT2AP2RX7ELANEALDH1A1 | |
| SCHEMBL6133226 | 0.78 | P2RX7 (0.45) | MEN1KMT2AP2RX7ELANEALDH1A1 | |
| SCHEMBL10215486 | 0.75 | P2RX7 (0.47) | MEN1KMT2AP2RX7ALDH1A1HCRTR1 | |
| SCHEMBL12018713 | 0.75 | P2RX7 (0.46) | MEN1KMT2AP2RX7ELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683697-B1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN ATLANTIS HOLDINGS SA (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN ATLANTIS HOLDINGS SA (CH) | 2016-09-01 | — | — | US | disclosed |
| US-9382216-B2 | Substituted morpholines as modulators for the calcium sensing receptor | LUPIN LIMITED (IN) | 2016-07-05 | — | — | US | disclosed |
| EP-2683697-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | Lupin Limited (IN) | 2014-01-15 | — | — | EP | disclosed |
| US-20130345213-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN LIMITED (IN) | 2013-12-26 | — | — | US | disclosed |
| WO-2012120476-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | LUPIN LIMITED (IN) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345213-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | CASR, RYR1, RYR2 | MEN1 344/4885KMT2A 3755/4885P2RX7 207/4885 |
| US-20160250219-A1 | SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR | CASR, RYR1, RYR2 | MEN1 344/4885KMT2A 3755/4885P2RX7 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.